New research suggests that people who discontinue new weight-loss injections like Mounjaro or Wegovy may regain shed pounds far faster than those who stop traditional diet and exercise regimens.
Published data in a major medical journal points out that while obese people often shed a large proportion of their body weight while using the jabs, the mass comes back at an average rate of nearly a kilo each month upon discontinuation.
"Users buying these drugs need to be aware of the risk of quick weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment mass within about 18 months.
Weighing Approaches
The study, which examined 37 of trials involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with older methods.
The team note that individuals who shed pounds through diet and exercise usually see a less rapid weight regain—approximately 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Doctors believe the mode of action of the jabs is key to understanding the amplified rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which moderates hunger.
"Long-term administration of the hormone concentrations several times higher than the body's typical production might result in the body to produce less of its own natural hormone, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' results in hunger is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by recommended lifestyle changes.
Professionals argue that, considering the likelihood of relapse, the treatment is often long-term.
This perspective is reinforced by pharmaceutical companies, who say that the results "highlight the persistent character of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
People who have discontinued the medication describe a powerful resurgence of appetite.
"It was like something that goes on and you're instantly ravenous," recalled one woman.
The struggle is exacerbated if users have not established permanent dietary or behavioural changes during treatment.
Significant Use
Survey data suggest that millions of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is higher among women compared to males.
- The 40s and 50s demographic shows the greatest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, clinicians emphasize that while these medications are effective tools for shedding pounds, they are not a magic solution and long-term success relies on integrated lifestyle management.
